Skip to main content

Table 1 Clinical evidence for adoptive transfer of CMV-specific T cells

From: Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation

Reference

Method

No. of patients

Results

Dose

In vitro stimulation and expansion

Riddell et al. (1992) [22]

Allogeneic CMV-spec. CD8+ clones

3

3/3 prevention of viremia and pneumonia

3.3 × 107–109 cells/m2

Walter et al. (1995) [45]

Allogeneic CMV-spec. CD8+ clones phase I

14 (11)

11/11 prevention of CMV infection

3.3 × 107–109 cells/m2

Einsele et al. (2002) [23]

Allogeneic CMV-spec. polyclonal CD8+ and CD4+ T cells

8

5/7 evaluable patients eliminated infection

107 cells/m2

Peggs et al. (2003) [46]

Allogeneic CMV-specific polyclonal CD8+ and CD4+ T cells

16

14/16 no viral reactivation, reconstitution of antiviral immunity

105 cells/kg

Perruccio et al. (2005) [56]

Allogeneic CMV-specific CD4+ clones

25 prophylaxis

7/25 patients had CMV-reactivation, 5/25 patients developed CMV-disease (3 eliminated infection)

105–3 × 106 cells/kg

Meji et al. (2012) [57]

CMV-specific polyclonal CD8+ and CD4+ T cells phase I/II

6

6/6 patients eliminated infection

0.9 × 104–3.1 × 105 cells/kg

Pei et al. (2017) [58]

CMV-specific cytokine induce effector cells phase I

32

27/32 responded

0.66–15.41 × 107 CD8+ and 0.68–9.25 × 105 CD4+

Withers et al. (2017 and 2018) [55, 59]

CMV-specific third-party CD8+ and CD4+ T cells phase I

27

26/27 responded

1.37–5.0 × 107 cells/m2

Direct isolation via peptide-HLA multimers

Cobbold et al. (2005) [47]

Allogeneic CMV-specific CD8+ T cells using MHC-I-tetramers

9

8/9 patients eliminated infection

1.2–33 × 103 cells/kg

Schmitt et al. (2011) [48]

Allogeneic CMV-specific CD8+ T cells using MHC-I-streptamers

2

2/2 control of CMV-viremia

0.37 and 2.2 × 105 cells/kg

Uhlin et al. (2012) [60]

Allogeneic CMV-specific CD8+ T cells using MHC-I-pentamers

5

4/5 responders

0.8–24.6 × 104 cells/kg

Blyth et al. (2013) [61]

Allogeneic CMV-specific polyclonal CD8+ and CD4+ T cells phase II

50 Prophylaxis

41/50 did not require CMV-directed pharmacotherapy

2 × 107 cells/m2

Neuenhahn et al. (2017) [12]

Allogeneic CMV-specific CD8+ T cells using MHC-I-streptamers phase I/IIa

16

Stem cell donor-derived: 7/7 responders third-party transfer: 5/8 responders

6.3 × 106 cells (HSCT donor) 1.4 × 107 cells (third-party donor)

Direct isolation via cytokine-capture technique

Feuchtingeret al. (2010) [28]

CMV-specific polyclonal CD8+ and CD4+ T cells

18

15/18 responders

1.2–166 × 103 cells/kg

Peggs et al. (2011) [62]

CMV-specific polyclonal CD8+ and CD4+ T cells phase I/II

18

Prophylaxis: 6/7 virus-free Pre-emptive: 2/11 required no antiviral drug treatment

Median: 3.5 × 104 cells/kg

Kàllay et al. (2018) [43]

CMV-specific polyclonal CD8+ and CD4+ T cells

3

2/3 viral clearance 1/3 decrease in viral load

7.5–16.2 × 104 cells/kg